

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



30th October, 2026

To,
The Manager,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 539206; Company Symbol: GVBL

Sub: Outcome of the Board meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on today i.e. 30th October 2026.

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held on Wednesday, 30th October 2026, at the corporate office of the Company situated at G-74, Pushkar Enclave, Paschim Vihar, Delhi - 110063 to consider and approve the following matter(s): -

1. Considered and approved the standalone Un-audited financial results of the company for the quarter and half year ended 30th September 2026. A copy of the said standalone un-audited financial results along with the limited review report from Statutory Auditor thereon is enclosed herewith.

The meeting of the Board of Directors commenced at 05:15 P.M. and concluded at 05:45 P.M.

This is for your information and record please.

Thanking you,
Yours sincerely,

For Genomic Valley Biotech Limited

Yogesh
Agrawal

Digitally signed by
Yogesh Agrawal
Date: 2026.10.30
17:48:26 +05'30'

Yogesh Agrawal
Managing Director
DIN : 01165288

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email : BRIJBHUSHAN_CA@YAHOO.CO.IN

LIMITED REVIEW REPORT

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheeri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.


Subject: Limited Review Report on the Un-Audited Financial Results for the Quarter and half year ended on September 30, 2026, and year to date from April 01, 2026 to September 30, 2026

We have reviewed the accompanying statement of unaudited financial results for **the Quarter and half year ended on September 30, 2026 and year to date from April 01, 2026 to September 30, 2026** ('the statement') of Genomic Valley Biotech Limited ('the Company') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("Listing Regulations").

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards, prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended ("Listing Regulations") including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ANDROS & CO.,
Chartered Accountants



Brij Bhushan Garg
Partner

UDIN: 260848650CFSSF8818

FRN No. 008976N
Membership No. 084865
PR No. 019517

Place: Delhi
Date: 30.10.2026

Statement of Asset and Liabilities

Particulars	Current half year ended	Previous year ended
	30-09-2026	31-03-2026
	Un-Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	33,940.23	49,940.23
Capital work in progress		
Other Intangible assets		
Intangible assets under development		
Financial assets		
Investment	-	-
Loans	1,54,11,439.00	1,54,11,439.00
Security Deposits	50,000.00	50,000.00
Other financial assets	-	-
Deferred tax assets (Net)	-	-
Other non current assets	-	-
Total Non-Current Assets	1,54,95,379.23	1,55,11,379.23
Current Assets		
Inventories	28,42,425.00	28,42,425.00
Financial Assets:		
Investments	-	-
Trade Receivables	2,36,25,845.00	2,31,77,445.00
Cash and Cash equivalents	3,626.00	42,936.00
Other Balances with banks	4,51,388.72	2,19,329.08
Loans		
Other financial assets		
Other Current assets	8,66,704.40	7,02,160.00
Total Current Assets	2,77,89,989.12	2,69,84,295.08
Total Assets	4,32,85,368.35	4,24,95,674.31
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	3,05,45,000.00	3,05,45,000.00
Othe Equity	86,88,005.35	87,39,574.31
Total Equity	3,92,33,005.35	3,92,84,574.31
Non Current Liabilities		
Financial liabilities		
Borrowings		
Security Deposits		
Other Financials liabilities		
Deferred tax liabilities (Net)	2,652.26	2,652.26
Provisions		
Other Non Current liabilities		
Total Non Current Liabilities	2,652.26	2,652.26
Current Liabilities		
Financial liabilities		
Borrowings		-
Trade Payables	10,620.00	59,000.00
Other Financials liabilities	26,54,337.75	26,54,337.75
Provisions	1,00,000.00	1,10,000.00
Other Current liabilities	12,84,752.99	3,85,109.99
Total Current Liabilities	40,49,710.74	32,08,447.74
TOTAL EQUITY AND LIABILITIES	4,32,85,368.35	4,24,95,674.31

Notes :


- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 30-10-2026. The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Comapnies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Floriculture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited

Yogesh Agrawal

Yogesh Agrawal
(Managing Director)
DIN-01165288

Add: G-74 Pushkar Enclave
Paschim Vihar, New Delhi-110063



Place : Delhi
Dated : 30-10-2026

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029


Genomic Valley Biotech Limited today reported its financial performance for the quarter and six months ended
30 September 2026

Highlights of the Un-Audited Financial Results as compared to the previous year are:

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for corresponding period ended	Previous year ended
		30-Sep-26 Un-Audited	30-Jun-26 Un-Audited	30-Sep-25 Un-Audited	30-Sep-26 Un-Audited	30-Sep-25 Un-Audited	31-Mar-26 Audited
I	Revenue From Operations	-	3,80,000	9,00,000	3,80,000	18,00,000	26,75,000
II	Other Income	-	-	-	-	-	-
III	Total Revenue (I+II)	-	3,80,000	9,00,000	3,80,000	18,00,000	26,75,000
IV	Expenses						
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee benefits expense	45,000	69,000	3,75,000	1,14,000	7,89,000	10,59,000
	Financial costs	-	-	-	-	-	-
	Depreciation and amortization expense	8,000	8,000	8,000	16,000	16,000	37,064
	Other expenses	1,44,731	1,56,838	4,83,951	3,01,569	7,15,420	11,78,525
	Total Expenses (IV)	1,97,731	2,33,838	8,66,951	4,31,569	15,20,420	22,74,590
V	Profit / (Loss) before exceptional item and tax (III-IV)	-1,97,731	1,46,162	33,049	-51,569	2,79,580	4,00,410
VI	Exceptional Item	-	-	-	-	-	-
VII	Profit/loss before Tax (V-VI)	-1,97,731	1,46,162	33,049	-51,569	2,79,580	4,00,410
VIII	Tax expenses						
	(1) Current Tax	-	-	-	-	-	1,00,000
	(2) Deferred Tax	-	-	-	-	-	-2,631
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	-1,97,731	1,46,162	33,049	-51,569	2,79,580	3,03,041
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	-1,97,731	1,46,162	33,049	-51,569	2,79,580	3,03,041
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	-1,97,731	1,46,162	33,049	-51,569	2,79,580	3,03,041
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500
XVII	Earning Per Equity Share (for continuing operation):						
	1) Basic	-0.06	0.05	0.01	-0.02	0.09	0.10
	2) Diluted	-0.06	0.05	0.01	-0.02	0.09	0.10
XVIII	Earning Per Equity Share (for discontinued operation):						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):						
	1) Basic	-0.06	0.05	0.01	-0.02	0.09	0.10
	2) Diluted	-0.06	0.05	0.01	-0.02	0.09	0.10

For and on behalf of the Board of Genomic Valley Biotech Limited



Yogesh Agrawal
(Managing Director)
DIN-01165288

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHARI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER, 2026

	Particulars	Amount in INR		
		30.09.2026	30.09.2025	31.03.2026
A.	CASH FLOW FROM OPERATING ACTIVITIES			
	Net Profit As Statement Profit & Loss	-51,569	2,79,580	4,00,410
	Adjustment For			
	Discount received	-	-	-
	Non-Operating Income	-	-	-
	Interest Income	-	-	-
	Gain/(Loss) on sale of assets	-	-	-
	Depreciation and Amortisation Expenses	16,000	16,000	37,064
	Operating Profit Before Change in Working Capital	-35,569	2,95,580	4,37,475
	ADJUSTMENTS FOR WORKING CAPITAL:			
	Increase/Decrease in Loans and Advances	-	2,00,000	18,00,000
	Increase/ Decrease in Inventories	-	-	-
	Increase/Decrease in Security Deposits	-	-	-
	Increase/Decrease in Trade Receivables	-4,48,400	-	-10,32,500
	Increase/Decrease in Other Current Assets	-1,64,544	-3,42,500	75,414
	Increase/Decrease in Current Liabilities	8,41,263	-5,34,627	-13,72,991
	CASH GENERATED FROM OPERATIONS	1,92,750	-3,81,547	-92,603
	Taxes Paid			97,369
	Total (A)	1,92,750	-3,81,547	-1,89,972
B.	CASH FLOW FROM INVESTING ACTIVITIES			
	Additions/Sales to fixed assets	-	-	-
	Purchase/Sell of Investments	-	-	-
	Discount received	-	-	-
	Non-Operating Income	-	-	-
	Interest Income	-	-	-
	Total (B)	-	-	-
C.	CASH FLOWS FROM FINANCING ACTIVITIES			
	Proceeds from Borrowings	-	-	-
	Preliminary Expenses	-	-	-
	Total (C)	-	-	-
	NET CASH FLOWS DURING THE YEAR (A+B+C)	1,92,750	-3,81,547	-1,89,972
	Cash and Cash Equivalents (Opening Balance)	2,62,265	4,52,237	4,52,237
	Cash and Cash Equivalents (Closing Balance)	4,55,015	70,690	2,62,265

For and on behalf of the Board of Genomic Valley Biotech Limited


Yogesh Agrawal
(Managing Director)
DIN-01165288

